Post-Approval Isnt AfterIts Where Patent Risk Gets Real
Most pharma teams treat patent strategy like a pre-approval exercise: file early, win early, move on. But the period after approval is where regulatory and IP risk quietly compoundsoften faster th…

Post-approval is where the real IP game starts.
Most teams obsess over getting to approval—then quietly assume the hard part is over. It isn’t. In the months and years after launch, your product becomes a target: for generic challengers, for “evergre…

Pharma exclusivity is a chess gameuntil someone files suit.
If youre building a patent strategy, the goal isnt just to have patents. Its to defend exclusivity without triggering the kind of litigation that drains time, cash, and credibility. In today…

From Humira to Keytruda: The Blueprint for Surviving the Composition-of-Matter Cliff
The composition-of-matter cliff isnt a metaphorits a calendar. For pharma companies, its the moment when the core patent protection that blocks generic and biosimilar …

Pharmas patent cliff isnt just about expiring patents. Its about how those patents are writtenand how quickly the industry can rewrite the story before generic competition arrives.
Thats the hidden lever behind method of use patents: a legal mechanism …

The patent dance isnt a metaphorits a strategy.
Before the first brief is filed, biosimilar developers are already in a high-stakes choreography: timing, evidence, regulatory posture, and patent positioning all move in lockstep. And if you think the …

Drug patent cliffs arent just legal eventstheyre data events.
Most teams still treat patent expiration and litigation risk as something you react to once the clock is already ticking. But in pharma, timing is everything: the earlier you can anticipat…

Patent thickets arent just a legal problemtheyre a business strategy problem.
If youve ever watched a launch timeline slip because of a web of overlapping Orange Book listings, continuation filings, and just one more infringement theory, you already …

Blockbuster patents arent just ownedtheyre engineered. And if youre trying to build a competitive design-around, the real battleground isnt the active ingredient. Its the formulation.
In the last decade, the industrys patent landscape has shifted from …

Patent risk isnt just a legal issueits a board-level risk.
In pharma, IP litigation can feel like a distant storm: a flurry of filings, expert declarations, and courtroom dates that executives watch from the sidelines. But for boards, the question is…